Tucson, ARIZONA5 Active Studies

Follicular Lymphoma Clinical Trials in Tucson, ARIZONA

Find 5 actively recruiting follicular lymphoma clinical trials in Tucson, ARIZONA. Connect with local research sites and explore new treatment options.

5
Active Trials
5
Sponsors
1,942
Enrolling

Recruiting Follicular Lymphoma Studies in Tucson

RecruitingTucson, ARIZONANCT04224493

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after ...

612 participants
Epizyme, Inc.
View Study Details
RecruitingTucson, ARIZONANCT06337318

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a p...

600 participants
National Cancer Institute (NCI)
View Study Details
RecruitingTucson, ARIZONANCT06091254

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin...

478 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingTucson, ARIZONANCT07032662

IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP....

162 participants
Immunovant Sciences GmbH
View Study Details
RecruitingTucson, ARIZONANCT06425302

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL)....

90 participants
Celgene
View Study Details

About Follicular Lymphoma Clinical Trials in Tucson

Follicular lymphoma is the second most common type of non-Hodgkin lymphoma and is typically a slow-growing (indolent) cancer. It develops from B-cells in the lymph nodes. Treatment ranges from watchful waiting to immunotherapy, chemotherapy, and targeted agents.

There are currently 5 follicular lymphoma clinical trials recruiting participants in Tucson, ARIZONA. These studies are seeking a combined 1,942 participants. Research is being sponsored by Epizyme, Inc., National Cancer Institute (NCI), Regeneron Pharmaceuticals and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Follicular Lymphoma Clinical Trials in Tucson — FAQ

Are there follicular lymphoma clinical trials in Tucson?

Yes, there are 5 follicular lymphoma clinical trials currently recruiting in Tucson, ARIZONA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Tucson?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you about next steps.

Are clinical trials in Tucson free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tucson studies also compensate for your time and travel.

What follicular lymphoma treatments are being tested?

The 5 active trials in Tucson are testing new therapies including novel drugs, biologics, and treatment approaches for follicular lymphoma.

Data updated March 2, 2026 from ClinicalTrials.gov